1. Home
  2. GRX vs CRDF Comparison

GRX vs CRDF Comparison

Compare GRX & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Gabelli Healthcare & Wellness Trust of Beneficial Interest

GRX

The Gabelli Healthcare & Wellness Trust of Beneficial Interest

HOLD

Current Price

$9.10

Market Cap

132.9M

Sector

Finance

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.52

Market Cap

114.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRX
CRDF
Founded
N/A
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
132.9M
114.2M
IPO Year
2007
2012

Fundamental Metrics

Financial Performance
Metric
GRX
CRDF
Price
$9.10
$1.52
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.63
AVG Volume (30 Days)
19.7K
1.5M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.37
EPS
N/A
N/A
Revenue
N/A
$365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
49.61
52 Week Low
$8.86
$1.35
52 Week High
$10.05
$4.56

Technical Indicators

Market Signals
Indicator
GRX
CRDF
Relative Strength Index (RSI) 51.57 43.31
Support Level $8.93 N/A
Resistance Level $9.23 $1.76
Average True Range (ATR) 0.10 0.18
MACD 0.01 -0.03
Stochastic Oscillator 74.55 26.00

Price Performance

Historical Comparison
GRX
CRDF

About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest

Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: